Sodium-glucose Cotransporter 2 Inhibitor–induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient

2016 ◽  
Vol 351 (6) ◽  
pp. 634-635 ◽  
Author(s):  
Edna M. Juarez Ramirez Tello ◽  
Menfil A. Orellana-Barrios ◽  
Kenneth Nugent
Keyword(s):  
Diabetic Patient ◽  
Diabetic Ketoacidosis ◽  
Sodium Glucose Cotransporter ◽  
Type 2 Diabetic

scholarly journals Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Erasmia Sampani ◽  
Pantelis Sarafidis ◽  
Chrysostomos Dimitriadis ◽  
Efstratios Kasimatis ◽  
Dimitra Daikidou ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Diabetic Patient ◽  
Diabetic Ketoacidosis ◽  
Euglycemic Diabetic Ketoacidosis ◽  
Type 2 Diabetic

scholarly journals Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Eleni Papadokostaki ◽  
Evangelos Liberopoulos
Keyword(s):  
Type 2 Diabetes ◽  
Adverse Effect ◽  
Colon Cancer ◽  
Diabetic Ketoacidosis ◽  
Sglt2 Inhibitor ◽  
Sglt2 Inhibitors ◽  
Sodium Glucose Cotransporter ◽  
Euglycemic Diabetic Ketoacidosis ◽  
Type 2 Diabetic

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is steadily increasing. SGLT2 inhibitors are associated with weight loss, lowering of blood pressure, and low hypoglycemia risk along with beneficial cardiovascular and renoprotective effects. In view of the increasing use of SGLT2i, physicians must be aware of their adverse effects. Euglycemic diabetic ketoacidosis (euDKA) is a well-recognized adverse effect of SGLT2i. We present here a case of euglycemic diabetic ketoacidosis secondary to dapagliflozin use in a type 2 diabetic patient with colon cancer. To the best of our knowledge, this is first report of SGLT2 inhibitor-associated euDKA in a patient with underlying colon cancer.

Prevalence and predictive factors of advanced fibrosis in type 2 diabetic patient in a majoritally abstinent population of alcohol

2019 ◽  
Author(s):  
Halima Fennoun ◽  
Mansouri Souhaila El ◽  
Mohamed Tahiri ◽  
Aziz Siham El ◽  
Farid Haddad ◽  
...  
Keyword(s):  
Diabetic Patient ◽  
Predictive Factors ◽  
Advanced Fibrosis ◽  
Type 2 Diabetic

scholarly journals Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis

2021 ◽  
Vol 11 (2) ◽  
pp. 216-218
Author(s):  
Marta Brandão Calçada ◽  
Luís Fernandes ◽  
Rita Soares Costa ◽  
Sara Montezinho ◽  
Filipa Martins Duarte ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Drug Class ◽  
Clinical Suspicion ◽  
Laboratory Findings ◽  
Sodium Glucose Cotransporter ◽  
History Of ◽  
High Degree ◽  
Euglycemic Diabetic Ketoacidosis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved drug class for the treatment of type 2 diabetes mellitus (T2D). Although they are largely well-tolerated, their intake has been associated with euglycemic diabetic ketoacidosis (DKA) in some rare cases. We report the case of a 70-year-old male with type 2 diabetes and no history of DKA, who started therapy with empagliflozin one day before presenting with acute pancreatitis and laboratory findings consistent with euglycemic DKA. SGLT2i can induce euglycemic DKA from the first dose. Given the atypical presentation, a high degree of clinical suspicion is required to recognize this complication.

A Case of Gabapentin-induced Myoclonus in a Type 2 Diabetic Patient with End-stage Renal Disease

2011 ◽  
Vol 12 (3) ◽  
pp. 171
Author(s):  
Eun Yeong Choe ◽  
Byung-Wan Lee ◽  
Kyeong Hye Park ◽  
Hannah Seok ◽  
Daham Kim ◽  
...  
Keyword(s):  
Renal Disease ◽  
Diabetic Patient ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document